Research programme: personalised targeted immunotherapy - BriaCell Therapeutics

Drug Profile

Research programme: personalised targeted immunotherapy - BriaCell Therapeutics

Alternative Names: Bria-OTS; Off-the-Shelf Personalized Immunotherapy

Latest Information Update: 26 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BriaCell Therapeutics Corp
  • Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Cell replacements; Gene transference; Granulocyte-macrophage colony-stimulating factor expression stimulants; Interferon alpha expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Breast cancer

Most Recent Events

  • 21 Jun 2018 Research programme: personalised targeted immunotherapy - BriaCell Therapeutics is available for licensing as of 21 Jun 2018.
  • 06 Feb 2018 BriaCell therapeutics plans a phase I trial for Breast cancer (BriaCell website, February 2017)
  • 31 Jan 2018 Early research in Breast cancer in USA (parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top